Clinical hold for Arrowhead's HBV therapy

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) fell $1.91 (31%) to $4.20 on Wednesday after it said FDA placed a clinical hold on

Read the full 201 word article

User Sign In